Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Ben Ehst, MD</span> Oct 29 Beneath the Itch: The Role of Type 2 Inflammation and a Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Ben Ehst, MD 12:15 pm - 1:15 pm
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Marc Serota, MD</span> Oct 30 A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Marc Serota, MD 12:15 pm - 1:15 pm
A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Karan Lal, DO</span> Nov 3 A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Karan Lal, DO 12:15 pm - 12:45 pm
DUPIXENT<sup>@</sup> (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Omar Noor, MD</span> Nov 3 DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Omar Noor, MD 12:15 pm - 1:15 pm
Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age<br> <span style="color: #009B77;">by Autumn Burnette, MD</span> Nov 4 Clinical Case Discussion: A Pediatric Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Autumn Burnette, MD 12:15 pm - 1:15 pm
Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age <br> <span style="color: #009B77;">by Amy Spizuoco, DO</span> Nov 6 Clinical Case Discussion: An Adolescent Patient with Uncontrolled Moderate-to-Severe Atopic Dermatitis and a Treatment Option for Appropriate Patients 6+ Months of Age by Amy Spizuoco, DO 12:15 pm - 1:15 pm
Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP)<br> <span style="color: #009B77;">by Daniel Butler, MD</span> Nov 6 Pearls and Common Challenges for the Diagnosis of Bullous Pemphigoid (BP) by Daniel Butler, MD 12:15 pm - 1:15 pm
Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age<br> <span style="color: #009B77;">by Leigh Ann Pansch, NP</span> Nov 10 Diagnosing and Assessing Chronic Spontaneous Urticaria (CSU) and a Treatment Option for Appropriate CSU Patients 12+ Years of Age by Leigh Ann Pansch, NP 12:15 pm - 1:15 pm
DUPIXENT<sup>@</sup> (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Lakshi Aldredge, NP</span> Nov 10 DUPIXENT@ (dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Lakshi Aldredge, NP 12:15 pm - 1:15 pm
DUPIXENT<sup>@</sup>(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation<br> <span style="color: #009B77;">by Sandri Johnson, NP</span> Nov 12 DUPIXENT@(dupilumab) Patient Story followed by A Treatment Option for Appropriate Patients with Certain Skin Diseases Driven in Part by Type 2 Inflammation by Sandri Johnson, NP 12:15 pm - 1:15 pm
